Abstract Objectives MiR-30b, miR-30c, miR-221 and miR-222 are known to induce gefitinib
resistance in lung cancer cell lines with activation of mutations in the epidermal growth factor …

The EGFR pathway has emerged as a key target in non-small-cell lung cancer. EGF
receptor (EGFR) inhibition in non-small-cell lung cancer is achieved via small molecular …

Background Nearly 85% of lung-cancer-specific epidermal growth factor receptor (EGFR)
sensitive mutations comprise a substitution at position 858 (21L858R) and deletion mutants …

The mapping of the human genome and subsequent advancements in genetic technology
had provided clinicians and scientists an understanding of the genetic basis of altered drug …

The personalized medicine revolution is occurring for cancer chemotherapy. Biomarkers are
increasingly capable of distinguishing genotypic or phenotypic traits of individual tumors …

Background. Since the mapping of the human genome in 2003, the development of
biomarker targeted therapy and clinical adoption of “personalized medicine” has …

The epidermal growth factor receptor (EGFR), a member of the HER family of receptors, has
become a well-established target for the treatment of patients with non-small cell lung …

The optimal development of novel molecularly targeted agents for the treatment of cancer
requires a re-evaluation of the current drug development paradigm. Selection of patients …

The identification of certain molecular mechanisms underlying lung carcinogenesis and
progression has led to the development of targeted agents against different families of …

Patients with non‐small‐cell lung cancer (NSCLC) appear to gain particular benefit from
treatment with epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitors (TKI) if …